The worldwide Opioid-Induced Constipation market touched xxx million USD with a CAGR xx % from 2015-2019 around the world. In the future, it is predicted to reach xxx million USD in 2020 with a CAGR xx % from 2020 to 2025.
Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.
The classification of Opioid-Induced Constipation includes Methylnaltrexone Bromide, Lubiprostone, Naloxegol and other OTC drugs. The revenue proportion of Lubiprostone in 2017 is about 33%, and the proportion of OTC drugs is in about 34%.
Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.
s the report focuses on global Opioid-Induced Constipation market, mainly in Europe and Asia Pacific, North America, Middle East and Africa, and South America. This report segmented the market on the basis of regions, manufacturers, applications, and type.
in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
In market segmentation by manufacturers, the report covers the following companies-
Takeda Pharmaceuticals
Bayer
Sanofi
Mallinckrodt
Salix (Bausch Health)
AstraZeneca
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
In market segmentation by geographical regions, the report has analyzed the following regions-
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Columbia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
In market segmentation by types covers:
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
In market segmentation by applications :
Hospital
Pharmacy
Apart from the drivers, restraints, and opportunities, the report also offers competitive landscape, including various growth strategies adopted by profiled players for establishing significant position in the industry. The segmentation included in the comprehensive report will help respectable manufacturers to set up their processing units in the regions and increase their global presence. This would also benefit the industry and increase the company\'s product portfolio.
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Opioid-Induced Constipation market for the forecast period 2020 - 2025?
• What are the driving forces in the Opioid-Induced Constipation market for the forecast period 2020 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Opioid-Induced Constipation industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?